Matthew Pianko is a Hematology physician affiliated with University of Michigan. OpenAlex indexes 88 publications with 1,043 citations (h-index 16).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1500 E Medical Center Dr
B1 Floor Cancer Recep 'B'
Ann Arbor, MI 481095911
Telephone
734-647-8901Registry record last updated 3 Jan 2019.
Industry payments
12 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Kite Pharma, Inc.Program year202510 payments$10,691openpaymentsdata.cms.gov ↗
- E.R. Squibb & Sons, L.L.C.Program year20256 payments
- PFIZER INC.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
48.1%Thalidomide Analog43%Revlimid70%Lenalidomide19%Pomalyst11%Part D≥82 patientsProteasome Inhibitor4%Ninlaro100%Part D<11 patients+ 1 more class in this area
Dermatology
15.6%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor15.6%Acyclovir100%Part D≥65 patientsSensory organs
11%Corticosteroid11%Dexamethasone100%Part D≥45 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup Analyses
Clinical Lymphoma Myeloma & Leukemia
2025 - Current experiences with teclistamab in patients with multiple myeloma and renal impairment
Expert Review of Hematology
2025 - Linvoseltamab in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) in the LINKER-MM1 Study: Longer Follow-up and Subgroup Analyses
Clinical Lymphoma Myeloma & Leukemia
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Moshe Talpaz, MD
University of Michigan
William Herman, MD
University of Michigan
Max Wicha, MD
University of Michigan
Dinesh Khanna, MD
University of Michigan
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”